( mmediately after strokewas induced th...)CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies,Health

mmediately after stroke was induced, those treated with arimoclomol recovered dramatically faster and more completely than those untreated regardless of when treatment was initiated. The results were highly statistically significant. In all of the sensory and motor skills tested, even animals whose arimoclomol treatment began 48 hours after stroke were approximately half-way to complete recovery by day seven after stroke, whereas motor skills of untreated animals were unimproved. These data suggest that arimoclomol can accelerate the repair of neurological damage caused by stroke.

Unlike arimoclomol, most other stroke drug candidates do not repair the damage caused by stroke, but instead attempt to limit the initial damage caused by stroke. These compounds typically work either by breaking up the clot that stops blood flow, known as thrombolytics, or by defending brain cells from the immediate damage caused by oxygen deprivation, known as neuroprotectants. Since the damage caused by the lack of oxygen is known to occur very early, both types of drug candidates must generally be administered no later than three hours after stroke in order to show significant therapeutic benefit in rats (the "therapeutic window"). Consistent with these animal studies is the fact that the only drug currently approved for stroke, tPA, must be administered in a therapeutic window no greater than three hours after the onset of stroke symptoms to be effective. According to the American Heart Association, less than 25% of the approximately 700,000 Americans who annually suffer stroke reach an emergency room within three hours of the stroke event, indicating the enormous advantage of a drug that could be effective if administered after the three-hour therapeutic window.

According to CytRx's Chief Scientific Officer Jack Barber, Ph.D., "These preclinical results are so compelling that we have decided to evaluate the clinical benefit of arimoclomol in stroke recovery. Among other
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
3. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease